Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine ... the Albert Einstein College of Medicine and Associate Chairman ... Center. He is also Associate Director for Clinical ... Einstein Breast Cancer Working Group, a multidisciplinary group of ... He also serves as Vice Chair of the National ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... Calif. , May 17, 2013  Cellular ... has achieved 50% enrollment of the total projected ... evaluate the safety and preliminary efficacy of the ... therapy for Knee Osteoarthritis (KOA). To date the ... reported. The Phase I open label ...
(Date:5/17/2013)... FL (PRWEB) May 17, 2013 Men’s skin ... La-roche Posay ) and has been known to ... Although some men may be far from puberty, other acne ... clogging pores, causing breakouts, and threatening skin with unsightly acne ... advice from Men’s Health on how to reduce ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... offers a Bachelor of Science in Nursing ... College, Cutler Bay and Fortis College, Largo.  The accelerated ... already have a bachelor, associate or related higher degree ... is now enrolling candidates who wish to become professional ...
... Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: GNBT) announced ... Pozzilli at the University Campus Bio-Medico in Rome, Italy, will ... as it pertains to prediabetes at  the forthcoming International ... December 3 rd -8 th , 2011. ...
... The report "Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast ... analyzes and studies the major market drivers, restraints, and ... Browse market data tables and in-depth TOC ... Forecast in G8 Countries) (2010   - 2020). ...
Cached Biology Technology:Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students 2Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students 3Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 2Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 3Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai 4MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020 2MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020 3
(Date:5/20/2013)... SAN DIEGO (May 20, 2013) - A ... will headline the groundbreaking research that will be unveiled ... Biotechnology Conference (NBC). The meeting takes place Monday, May ... Diego Hotel and Marina. , "The main goal ... to fight against a pathogen that causes the disease", ...
(Date:5/19/2013)... California, Davis have engineered a strain of photosynthetic cyanobacteria ... report their findings today at the 113th General Meeting ... work, we used synthetic biology approaches to probe and ... energy for growth) cyanobacterial metabolism for the ability to ... researcher on the study. He is part of ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... converted to electricity, potentially providing power for sensors, recording devices ... Case Western Reserve University report. The finding is yet ... that could bring the creation of insect cyborgs touted ... science fiction and into reality. In this case, the power ...
... 5, 2012) -- Rice University,s Jane Grande-Allen, one ... of heart-valve tissue, has won an Established Investigator ... award, which includes a five-year research grant, recognizes ... an established record of accomplishments." Grande-Allen, associate professor ...
... type 2 diabetes and hypertension increases with cumulative levels ... study led by researchers from the Slone Epidemiology Center ... in the journal Circulation , was led by ... Boston University School of Public Health and the SEC. ...
Cached Biology News:Implanted biofuel cell converts bug's chemistry into electricity 2Implanted biofuel cell converts bug's chemistry into electricity 3Rice's Grande-Allen wins AHA Established Investigator Award 2Study finds air pollution linked to diabetes and hypertension in African-American women 2